Posttranslational modifications of histones such as methylation, acetylation, and phosphorylation regulate chromatin structure and gene expression. Here we show that protein kinase C-related kinase 1 (PRK1) phosphorylates histone H3 at threonine 11 (H3T11) upon ligand-dependent recruitment to androgen receptor (AR) target genes. PRK1 is pivotal to AR function since PRK1 knockdown or inhibition impedes AR-dependent transcription. Blocking PRK1 function abrogates androgen-induced H3T11 phosphorylation, and inhibits androgen-induced demethylation of histone H3. Moreover, serine 5-phosphorylated RNA polymerase II is no longer observed at AR target promoters. Phosphorylation of H3T11 by PRK1 accelerates demethylation by the Jumonji C (JmjC) domain-containing protein JMJD2C. Thus, phosphorylation of H3T11 by PRK1 establishes a novel chromatin mark for gene activation, identifying PRK1 as a gatekeeper of ARdependent transcription. Importantly, levels of PRK1 and phosphorylated H3T11 correlate with Gleason scores of prostate carcinomas. Finally, inhibition of PRK1 blocks AR-induced tumour cell proliferation, making PRK1 a promising therapeutic target. Keywords PRK1; androgen receptor; histone phosphorylation; prostate cancerThe N-terminal tails of histones are subject to a plethora of posttranslational modifications such as methylation, acetylation, and phosphorylation by specific chromatin-modifying enzymes1. During gene expression, these modifications influence chromatin structure to facilitate the assembly of the RNA polymerase II transcription machinery1 , 2. Androgen receptor (AR)-dependent gene expression is characterized by changes in chromatin

In contrast to mammals, zebrafish regenerate heart injuries via proliferation of cardiomyocytes located near the wound border. To identify regulators of cardiomyocyte proliferation, we used spatially resolved RNA sequencing (tomo-seq) and generated a high-resolution genome-wide atlas of gene expression in the regenerating zebrafish heart. Interestingly, we identified two wound border zones with distinct expression profiles, including the re-expression of embryonic cardiac genes and targets of bone morphogenetic protein (BMP) signaling. Endogenous BMP signaling has been reported to be detrimental to mammalian cardiac repair. In contrast, we find that genetic or chemical inhibition of BMP signaling in zebrafish reduces cardiomyocyte dedifferentiation and proliferation, ultimately compromising myocardial regeneration, while bmp2b overexpression is sufficient to enhance it. Our results provide a resource for further studies on the molecular regulation of cardiac regeneration and reveal intriguing differential cellular responses of cardiomyocytes to a conserved signaling pathway in regenerative versus non-regenerative hearts.

Barley yellow dwarf virus (BYDV) causes high yield losses in most of the major cereal crops worldwide. A source of very effective resistance was detected within the tetraploid wild species of Hordeum bulbosum. Interspecific crosses between a resistant H. bulbosum accession and H. vulgare cv. 'Igri' were performed to transfer this resistance into cultivated barley. Backcrosses to H. vulgare resulted in offspring which carried a single subterminal introgression of H. bulbosum chromatin on barley chromosome 3HL and proved to be fully resistant to BYDV-PAV, as inferred by ELISA values of zero or close to zero and lack of BYDV symptoms. Genetic analysis indicated a dominant inheritance of the BYDV-PAV resistance factor, which we propose to denote Ryd4 ( Hb ) . The identity and effect of Ryd4 ( Hb ) are discussed in relation to other known genes for BYDV resistance or tolerance, as well as the relevance of this gene for resistance breeding in barley.

The Kids-CAT was considered an efficient and valuable tool for assessing HRQoL in children and adolescents. The Kids-CAT Report promises to be a useful adjunct to standard clinical care with the potential to improve patient-physician communication, enabling pediatricians to evaluate and monitor their young patients' self-reported HRQoL.

IntroductionEnd-stage kidney disease (ESKD) is a major public health problem affecting more than 2 million people worldwide. It is one of the most severe chronic non-communicable diseases. Haemodialysis (HD) is the most common therapeutic option but is also associated with a risk of cardiovascular events, hospitalisation and suboptimal quality of life. Over the past decades, haemodiafiltration (HDF) has become available. Although high-dose HDF has shown some promising survival advantage compared to conventional HD, the evidence remains controversial. A Cochrane systematic review found, in low-quality trials, with various convective forms of dialysis, a reduction in cardiovascular, but not all-cause mortality and the effects on non-fatal cardiovascular events and hospitalisation were uncertain. In contrast, an individual patient data analysis suggested that high-dose HDF reduced both all-cause and cardiovascular mortality compared to HD. In view of these discrepant results, a definitive trial is required to determine whether high-dose HDF is preferable to high-flux HD. The comparison of high-dose HDF with high-flux HD (CONVINCE) study will assess the benefits and harms of high-dose HDF versus a conventional high-flux HD in adults with ESKD.Methods and analysisThis international, prospective, open label, randomised controlled trial aims to recruit 1800 ESKD adults treated with HD in nine European countries. Patients will be randomised 1:1 to high-dose HDF versus continuation of conventional high-flux HD. The primary outcome will be all-cause mortality at 3 years’ follow-up. Secondary outcomes will include cause-specific mortality, cardiovascular events, all-cause and infection-related hospitalisations, patient-reported outcomes (eg, health-related quality of life) and cost-effectiveness.Ethics and disseminationThe CONVINCE study will address the question of benefits and harms of high-dose HDF compared to high-flux HD for kidney replacement therapy in patients with ESKD with a focus on survival, patient perspectives and cost-effectiveness.Trial registration numberNetherlands National Trial Register (NTR 7138).

Background Technical innovation to assess patient-reported outcomes (PROs) facilitates their implementation in clinical practice. In particular, mobile applications (apps) allow PROs to be assessed outside of the clinical setting. A patient’s health status can be remotely monitored and evaluated after discharge, and their recovery process tracked. This is of particular interest for patients after knee arthroplasty, as the recovery phase after surgery usually takes place in an outpatient setting and requires a high level of patient engagement. Providing results of PRO assessments to patients in the form of a feedback report could increase patient engagement and may improve communication between health care professionals and patients. The aim of the study is to develop a PRO feedback report for mobile devices that is comprehensible and provides valuable information for patients after knee arthroplasty. Results In an iterative development process, our expert group developed two preliminary feedback reports (a text-based version and a graphical display) based on previous research results and practical experience. In a second step, we discussed these reports with orthopedic patients (n = 8) in terms of comprehensibility and value using semi-structured interviews and cognitive debriefing methods. Participants assessed the reports as informative, but had some difficulties in fully comprehending all of the information provided. Based on the feedback from patients, we modified both versions and reduced complexity to increase comprehensibility. Conclusions A PRO feedback report for patients for mobile app use has to take account of the heterogeneous user group, particularly demographics such as age and experience with mobile devices. Information should be presented in a simple way to be comprehensible and of value to patients. Technological advancements allow a simple default report to be set, something which enables patients interested in additional information to make customizations.

A novel and highly effective source of anthracnose resistance in narrow-leafed lupin was identified. Resistance was shown to be governed by a single dominant locus. Molecular markers have been developed, which can be used for selecting resistant genotypes in lupin breeding. A screening for anthracnose resistance of a set of plant genetic resources of narrow-leafed lupin (Lupinus angustifolius L.) identified the breeding line Bo7212 as being highly resistant to anthracnose (Colletotrichum lupini). Segregation analysis indicated that the resistance of Bo7212 is inherited by a single dominant locus. The corresponding resistance gene was given the designation LanrBo. Previously published molecular anchor markers allowed us to locate LanrBo on linkage group NLL-11 of narrow-leafed lupin. Using information from RNAseq data obtained with inoculated resistant vs. susceptible lupin entries as well as EST-sequence information from the model genome Lotus japonicus, additional SNP and EST markers linked to LanrBo were derived. A bracket of two LanrBo-flanking markers allows for precise marker-assisted selection of the novel resistance gene in narrow-leafed lupin breeding programs.

Original research article INTRODUCTIONInborn errors of metabolism are a group of rare, inherited disorders that, when left undiagnosed and untreated, can have devastating complications or even result in death. Infants with inborn metabolic diseases can be detected with biochemical testing even though they are often asymptomatic at birth. The goal of newborn screening (NBS) is to test all infants and properly identify those with a disorder early so that prompt therapy may be initiated. The American Academy of Pediatrics and the American College of Medical Genetics and Genomics recommend that all newborn infants undergo NBS shortly after birth.1,2 NBS testing began in the United States in the early 1960s with screening for phenylketonuria, and, over the years, it has evolved into a complex program testing for multiple conditions.3,4 The number of diseases screened for has greatly increased with the availability of new technology like tandem mass spectrometry, which measures amino acids for the diagnosis of aminoacidopathies and acylcarnitines for the detection of fatty acid oxidation defects and organic adicemias using dried blood spots on filter paper. 4 The collection technique and sample requirements remain the same as those originally established; therefore, the use of tandem mass spectrometry is an efficient method to screen for many conditions without increasing the amount of blood required. 5 In 2005, the American Academy of Pediatrics endorsed the recommendations by the American College of Medical Genetics and Genomics to increase the number of disorders included in the newborn screen core panel to 29 identified conditions and 25 additional conditions that are part of the differential diagnosis in the core panel. 1,2Most infants are born healthy and discharged within 1-2 days after birth. Infants born ill or prematurely require longer hospitalization and often receive intensive medical care in a neonatal intensive care unit (NICU). Various medical therapies, including total parenteral nutrition (TPN), provided in the NICU and the liver immaturity of the preterm infant's metabolic system contribute to higher rates of presumptive positive NBS results in this group. [6][7][8][9] This population requires special planning and investigation into the best practice for collecting the NBS specimen in a manner to reduce the potential of a false-positive result (FPR), a result that is out of the range established by the NBS laboratory (presumptively positive), and additional testing confirms that no disorder exists. However, despite the importance of this problem, there is limited literature about how to decrease the FPR in the NICU population.In 2009, the Clinical and Laboratory Standards Institute published the document entitled "Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns".10 This document Purpose: Newborn screening includes testing for many metabolic diseases. False-positive results are higher among neonatal intensive care unit infants, resulting in increased confirmatory testing and family...